Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025
December 15, 2025 — Eli Lilly and Company (NYSE: LLY) stock is starting the new week in focus as investors weigh a rapid-fire set of catalysts: a headline-grabbing Phase 3 result for next‑generation obesity drug retatrutide, fresh scrutiny around the